Clinical trialPhase 2Completed
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
- Outcome
- Finished, no results posted
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- June 2008
- Expected end
- December 2012
- Enrollment
- 597 participants
- Sites
- 25
- Primary outcomes
- Radiographic imaging and clinical evaluation will be used for tumor assessment
- Sponsor
- Industry
- Results posted
- No
- Last update
- 9 October 2015
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to determine if gastric/esophageal, lung, pancreatic, bladder and sarcoma patients show benefit from brivanib treatment. Patients who clearly do, stay on treatment. Those in which it is unclear will be randomized to continue or withdraw treatment to determine whether that benefit is related to brivanib
Papers 2
- Registry-listed results paperPhase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. DOI 10.1016/j.ejca.2019.07.024↗
- Builds on itAngiogenesis inhibitors for the treatment of epithelial ovarian cancer. DOI 10.1002/14651858.cd007930.pub3↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.